How “Sputnik V or Gam-Covid-Vac.” works. The Sputnik V vaccine, developed by Gamaleya National Research Institute of Epidemiology and Microbiology in Moscow, uses two different viruses that cause the common cold (adenovirus) in humans. · The adenoviruses are weakened so they cannot replicate in humans and cannot cause disease. · They are also modified so that the vaccine delivers a code for making the coronavirus spike protein. This aims to ensure that when the real virus tries to infect the body, it can mount an immune response in the form of antibodies. Sputnik uses a different vector for each of the two Jabs in a course of vaccination. Thus, using a different adenovirus vector may help create a more powerful immune response (compared with using the same vector twice), as it minimizes the risk of the immune system developing resistance to the initial vector. This provides immunity with a longer duration than vaccines using the same delivery mechanism for both shots, according to the Russian Direct Investment Fund (RDIF). Sputnik V is approved for use in over 55 countries with a total population of over 1.5 billion people, according to RDIF. Thus, an attempt has been made in this Booklet to describe“How Sputnik V or Gam-Covid-Vac. works.”, along with relevant Illustrations for better understanding! Although care has been taken while compiling and checking information given in this Booklet to ensure that it is accurate, and none shall be responsible, in any way, liable for contemporaneousness of this information or for any errors, omissions or inaccuracies in this publication. …Dr. H. K. Saboowala. M.B.(Bom) .M.R.S.H.(London)

This report from the Council for International Organizations of Medical Sciences (CIOMS) in collaboration with WHO covers the activities and outputs of the CIOMS/WHO Working Group on Vaccine Pharmacovigilance (2005-2010). This working group brought together experts from both industrialized and emerging countries representing regulatory agencies, vaccine industry, national and international public health bodies including WHO and CIOMS, academia and clinical care, contributing from their different perspectives. The report covers general terms and definitions for vaccine safety and discusses the application of such harmonized tools in vaccine safety surveillance and studies. As well, the report highlights case definitions for adverse events typically reported for vaccines. The report is addressed to those engaged in vaccine safety data collection and evaluation, and will also make a useful reading for others who want to familiarize themselves with vaccine safety terminology.

Offering a comprehensive review of the neuropathology of SARS-CoV-2, Neurological Care and the COVID-19 Pandemic provides up-to-date coverage of the wide array of the pathogen's neurological symptoms and complications. Drs. Ahmad Riad Ramadan and Gamaledin Osman discuss the neuropathology of SARS-CoV-2, its neurological manifestations, and the impact the pandemic has had on the care of patients with pre-existing neurological conditions. The authors also offer an overview of emerging treatments and vaccines, as well as ways healthcare systems have reorganized in order to respond to the pandemic. - Offers a thorough discussion of the impact the virus has had on the care of patients with neurological ailments, accompanied by recommendations on how to care for these patients. - Covers the impact of COVID-19 on patients with cerebrovascular diseases, seizures, demyelinating diseases, neuromuscular disorders, movement disorders, headache disorders, cognitive disorders, and neuro-oncological disorders. - Includes a detailed case study of how one healthcare system hit hard by COVID-19 successfully transformed itself to respond to the challenges imposed by the pandemic. - Consolidates today's available information on this timely topic into a single, convenient resource.

This comprehensive, authoritative treatise covers all aspects of mucosal vaccines including their development, mechanisms of action, molecular/cellular aspects, and practical applications. The contributing authors and editors of this one-of-a-kind book are very well known in their respective fields. Mucosal Vaccines is organized in a unique format in which basic, clinical, and practical aspects of the mucosal immune system for vaccine development are described and discussed. This project is endorsed by the Society for Mucosal Immunology. - Provides the latest views on mucosal vaccines - Applies basic principles to the development of new vaccines - Links basic, clinical, and practical aspects of mucosal vaccines to different infectious diseases - Unique and user-friendly organization

This book reviews the current knowledge of the globally circulating SARS-CoV-2 variants, highlights their distinct genetic characteristics and associated conformational changes in the viral spike protein, and profoundly discusses the mechanisms of convergent evolution that led to the rise of these mutated strains at different geographic regions during the Covid-19 pandemic. Furthermore, the book explores how these variants do and may impact the efficacy of established neutralizing antibody-based (nAb) vaccines and therapeutics by analysing latest in vivo and in vitro clinical data. Finally, the author discusses ways on how nAb Covid-19 treatment derived immune escape of SARS-CoV-2 could be minimized in the future.

Adenoviral Vectors for Gene Therapy, Second Edition provides detailed, comprehensive coverage of the gene delivery vehicles that are based on the adenovirus that is emerging as an important tool in gene therapy. These exciting new therapeutic agents have great potential for the treatment of disease, making gene therapy a fast-growing field for research. This book presents topics ranging from the basic biology of adenoviruses, through the construction and purification of adenoviral vectors, cutting-edge vectorology, and the use of adenoviral vectors in preclinical animal models, with final consideration of the regulatory issues surrounding human clinical gene therapy trials. This broad scope of information provides a solid overview of the field, allowing the reader to gain a complete understanding of the development and use of adenoviral vectors. - Provides complete coverage of the basic biology of adenoviruses, as well as their construction, propagation, and purification of adenoviral vectors - Introduces common strategies for the development of adenoviral vectors, along with cutting-edge methods for their improvement - Demonstrates noninvasive imaging of adenovirus-mediated gene transfer - Discusses utility of adenoviral vectors in animal disease models - Considers Federal Drug Administration regulations for human clinical trials

The discovery of adenoviruses naturally induced a new interest in viruses of the human upper respiratory tract since previously unknown viruses infecting this portion of the human body had not been identified in 20 years, and their unique characteristics stimulated investigations into the biochemical events essential for replication of animal viruses. Indeed, the field of molecular virology has evolved during the period since their dis covery, and adenoviruses have played a major role in this development. The exciting discoveries made with adenoviruses have had such a pro found effect on knowledge in basic virology, molecular biology, viral ge netics, human and animal infections, and cell transformation that this seemed a propitious time to have some of the major contributors review this field. This volume pays tribute to the late Wallace Rowe, Robert Huebner, and Maurice Hilleman whose initial discoveries of adenoviruses have tremendously enriched virology. Harold S. Ginsberg vii Contents Chapter 1 An Overview 1 Harold S. Ginsberg Chapter 2 The Architecture of Adenoviruses M. V. Nermut I. Introduction ................................... . 5 II. Chemical and Physical Properties ................... . 6 III. Virus Capsid: Composition and Organization .......... . 7 A. Hexon ..................................... . 10 B. Penton .................................... . 12 C. Other Virus Polypeptides Associated with the Capsid 13 D. Organization of the Capsid ..................... . 14 IV. Virus Core .................................... . 15 A. Evidence for the Core Shell ..................... . 17 B. Organization of the DNA-Protein Complex (Nucleoc- sid) ....................................... . 18 C. Tentative Model of the Adenovirus Nucleocapsid ... . 22 V. Model of the Adenovirion ......................... . 29 32 References .......................................... .